Sarah Anderson1, Lorie M Harper1, Jodie Dionne-Odom2, Gregory Halle-Ekane3, Alan T N Tita1. 1. Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, The University of Alabama at Birmingham, Birmingham, AL, USA. 2. Division of Infectious Diseases, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA. 3. Department of Obstetrics and Gynecology, Faculty of Health Sciences, University of Buea, Buea, Cameroon.
Abstract
OBJECTIVE: To compare prenatal maternal hepatitis B virus (HBV) screening and infant vaccination strategies to inform policy on HBV prevention in Sub-Saharan Africa. METHODS: A decision analytic model was created using previously published data to assess the ability of three intervention strategies to prevent HBV infection by age 10 years. Strategy 1 comprised of universal vaccination with a pentavalent vaccine (HBV, diphtheria, tetanus, pertussis, and Haemophilus influenzae) at age 6 weeks. Strategy 2 comprised of universal HBV vaccine at birth plus pentavalent vaccine. Strategy 3 comprised of maternal prenatal HBV screening and targeted HBV vaccine at birth for all exposed infants plus pentavalent vaccine. The reference strategy provided neither maternal screening nor infant vaccination. Rates of HBV infection and costs were compared. RESULTS: The reference strategy had an HBV infection rate of 2360 per 10 000 children. The HBV infection rate for strategy 1 was 813 per 10 000 children vaccinated (1547 cases prevented). Strategies 2 and 3 prevented an additional 384 cases and 362 cases, respectively. Inclusion of HBV vaccination at birth was the preferred approach at a willingness-to-pay threshold of US$150. CONCLUSION: Including a birth-dose HBV vaccine in the standard schedule was both cost-effective and prevented additional infections.
OBJECTIVE: To compare prenatal maternal hepatitis B virus (HBV) screening and infant vaccination strategies to inform policy on HBV prevention in Sub-Saharan Africa. METHODS: A decision analytic model was created using previously published data to assess the ability of three intervention strategies to prevent HBV infection by age 10 years. Strategy 1 comprised of universal vaccination with a pentavalent vaccine (HBV, diphtheria, tetanus, pertussis, and Haemophilus influenzae) at age 6 weeks. Strategy 2 comprised of universal HBV vaccine at birth plus pentavalent vaccine. Strategy 3 comprised of maternal prenatal HBV screening and targeted HBV vaccine at birth for all exposed infants plus pentavalent vaccine. The reference strategy provided neither maternal screening nor infant vaccination. Rates of HBV infection and costs were compared. RESULTS: The reference strategy had an HBV infection rate of 2360 per 10 000 children. The HBV infection rate for strategy 1 was 813 per 10 000 children vaccinated (1547 cases prevented). Strategies 2 and 3 prevented an additional 384 cases and 362 cases, respectively. Inclusion of HBV vaccination at birth was the preferred approach at a willingness-to-pay threshold of US$150. CONCLUSION: Including a birth-dose HBV vaccine in the standard schedule was both cost-effective and prevented additional infections.
Authors: Jodie Dionne-Odom; Rahel Mbah; Nicole J Rembert; Samuel Tancho; Gregory E Halle-Ekane; Comfort Enah; Thomas K Welty; Pius M Tih; Alan T N Tita Journal: Infect Dis Obstet Gynecol Date: 2016-08-08
Authors: Anna L McNaughton; José Lourenço; Louise Hattingh; Emily Adland; Samantha Daniels; Anriette Van Zyl; Connie S Akiror; Susan Wareing; Katie Jeffery; M Azim Ansari; Paul Klenerman; Philip J R Goulder; Sunetra Gupta; Pieter Jooste; Philippa C Matthews Journal: BMC Med Date: 2019-02-21 Impact factor: 8.775
Authors: Karin Geffert; Tongai G Maponga; Shimba Henerico; Wolfgang Preiser; Stella Mongella; August Stich; Samuel Kalluvya; Andreas Mueller; Christa Kasang Journal: BMC Infect Dis Date: 2020-06-05 Impact factor: 3.090
Authors: M Bierhoff; Kanokporn Pinyopornpanish; Kanokwan Pinyopornpanish; F Tongprasert; Arunrot Keereevijit; M Rijken; C S Chu; F Nosten; J Perfetto; M van Vugt; R Mcgready; C Angkurawaranon Journal: Open Forum Infect Dis Date: 2019-12-07 Impact factor: 3.835